4D Molecular Therapeutics (FDMT) PT Lowered to $40 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris lowered the price target on 4D Molecular Therapeutics (NASDAQ: FDMT) to $40.00 (from $63.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
